Startup profile · funding coverage
Amber
RNA-based multi-kilobase gene editing platform for diseases with high allelic diversity.
Stage
seed
Status
private
Coverage
full
Why Amber is interesting
Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.
Key facts
- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
- Co-investors not in VCT directory: Playground Global, Eli Lilly, RDF, Hummingbird Ventures, Pillar VC
Investors in our directory
Funds linked from Amber's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Amber's financing or category context.
FAQs about Amber
Funding context and why this company shows up in venture coverage.
Amber Bio builds RNA-writing gene editing tools that can make multi-kilobase corrections on RNA — aiming for reversible, safer edits than permanent DNA CRISPR changes, especially for diseases with many different mutations.
Directory-linked investors include Andreessen Horowitz (/fund/andreessen-horowitz) and ARCH Venture Partners (/fund/arch-venture-partners). Playground Global co-led the $26M seed round alongside a16z Bio + Health.
Amber Bio emerged from stealth in August 2023 with a $26M seed round and remains a private, preclinical biotech as of July 2026.
RNA edits are reversible and avoid permanent off-target DNA changes. Amber's thesis is that kilobase-scale RNA writing lets one drug address many pathogenic variants in allelic-diverse diseases.
No — Amber Bio remains a private company as of July 2026.
Last updated: 2026-07-24